BRIEF—Inflazome completes 40 million-euro Series B financing to develop NLRP3

Ireland-headquartered inflammasone company Inflazome today announces the successful completion of a Series B financing round of 40 million euros ($46 million).

The financing round was led by Forbion, with Longitude Capital and founding investors, Novartis Venture Fund and Fountain Healthcare Partners, also participating.

The proceeds will be used to advance the company’s first-in-class NLRP3 inflammasome inhibitors into multiple clinical trials in 2019, with next-generation compounds following thereafter.

Clinical and scientific data indicates that the NLRP3 inflammasome, a compelling biological target that regulates our innate immune response, is overactive in a broad range of serious medical conditions driven by harmful inflammation.

These include neurological disorders such as Alzheimer’s and Parkinson’s as well as inflammatory bowel disease, gout, osteoarthritis, liver, kidney and cardiovascular diseases; conditions often inadequately treated by current therapies.

Following the completion of the financing round, Dr Marco Boorsma, a general partner at Forbion, and Dr David Hirsch, a managing director and founder of Longitude Capital, have joined Inflazome’s board of directors.